Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of HRS9531 versus semaglutide in type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
CTR20243938Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531, semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Nov 2024; status: completed.
02
Drugs
HRS9531semaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20243938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243938.